Daiichi Sankyo’s AML Drug Among Nine CHMP Hopefuls
EMA Panel Poised To Adopt Opinion On EU-Wide Approval Of New Drugs
Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?
You may also be interested in...
What is in store for esketamine after third parties submit written interventions to the European Medicines Agency?
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.